Is BPC-157 legal to prescribe or buy in the US?

Compounding is how a pharmacy makes a drug that is not sold as a finished product. Federal law limits which raw ingredients a state-licensed pharmacy may use under section 503A. As FDA summarizes the rule, the bulk substance must comply with a USP or National Formulary monograph if one exists; if none exists, be a component of an FDA-approved drug; or, failing both, appear on FDA's list of bulk drug substances that can be used in compounding, the 503A bulks list.

BPC-157 fails all three. FDA's July 2026 presentation to its advisory committee states that there is no applicable USP or National Formulary monograph for BPC-157 in either form and that neither is a component of an FDA-approved drug. It is not on the 503A bulks list, which FDA can only change through notice-and-comment rulemaking. The same presentation adds that BPC-157 "is not a component of an approved product in any country, nor is it found in the European, Japanese, or International Pharmacopeias."

Because the list moves slowly, FDA has long run an interim policy that sorts nominated ingredients into categories. Category 1 substances may be compounded while FDA evaluates them, provided the conditions in its guidance are met. Category 2 substances raise significant safety risks, and for them FDA says it "would consider taking action against a compounder" under its general enforcement policies.

FDA placed BPC-157 in 503A Category 2 on September 29, 2023, according to its own safety-risks page as archived in January 2026. That page now lists BPC-157 under a separate heading, "Bulk drug substances nominated but withdrawn," because the nominators withdrew their nominations; the page shows a last update of April 22, 2026. FDA's category file, updated May 14, 2026, lists BPC-157 in no category at all.

Reading that removal as FDA clearing BPC-157 is a mistake. HHS's own October 2026 document states that BPC-157 was in Category 2 "from September 2023 until April 22, 2026, and neither the placement nor the removal changed their status under section 503A." Category 1 is the only category in which FDA said it would not act, and BPC-157 was never in it. FDA also kept its safety summary on the page word for word: compounded BPC-157 "may pose risk for immunogenicity for certain routes of administration," and the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans."

Even with the nominations withdrawn, FDA evaluated BPC-157 at its own discretion and brought it to the Pharmacy Compounding Advisory Committee on July 23, 2026, for one use: ulcerative colitis. FDA's recommendation, in its slides, was that BPC-157 free base and BPC-157 acetate "NOT be included on the 503A Bulks List." Its reasons, summarized from those slides:

• Effectiveness: one small randomized trial in 53 people with mild to moderate ulcerative colitis, reported only as a meeting abstract, in which the estimated difference from placebo had a confidence interval spanning zero. FDA found no studies of BPC-157 given by mouth, under the skin, in the nose or through the skin in people with the disease.
• Safety in people: FDA found no studies that gave BPC-157 to humans by the oral, subcutaneous, nasal or transdermal routes proposed. The human studies it did find were short, small and used other routes.
• Safety in animals: 28-day studies in rats and dogs found statistically significant signals FDA described as potentially related to blood clotting and the liver, and no longer studies were available.
• Reports from users: three adverse-event reports in FDA's database, including an emergency visit for shortness of breath. FDA said it was unclear whether BPC-157 caused them.
• Quality: FDA concluded neither form was well characterized chemically, and flagged the risk of an immune reaction to a 15-amino-acid peptide given by injection or into the nose.

The committee was asked to vote separately on the free base and the acetate, and it voted in favor of inclusion, according to the HHS document. FDA's meeting page, last updated August 6, 2026, had not posted minutes or a transcript when we checked on October 28, 2026, so we do not print a vote count. An advisory committee vote is advice to FDA; it does not put a substance on the list.

On October 28, 2026, the Department of Health and Human Services filed a notice for publication in the Federal Register on October 30 announcing a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," signed by the HHS Secretary. Its Appendix A lists six peptides, and BPC-157 is the first. Until each peptide is addressed in a final rule, HHS says it does not intend to take action against a state-licensed pharmacy, federal facility or licensed physician compounding with one of them when all of its conditions are met. For BPC-157, HHS limits the policy to BPC-157 acetate in subcutaneous, intramuscular, oral and topical dosage forms.

The conditions, in summary:

• A valid prescription for an individual patient, as section 503A already requires.
• The ingredient comes from an FDA-registered manufacturer and carries a certificate of analysis showing identity, purity, potency and tests for contaminants including endotoxins and heavy metals.
• One active ingredient per product, so that side effects can be traced to it.
• Oral products need documentation that the formulation is adequately absorbed.
• The only device packaged with the product is an FDA 510(k)-cleared syringe.
• The label reads "This is a compounded drug product. Not for resale."
• The compounder reports serious adverse events and quality problems to FDA's MedWatch program.

The notice calls the policy a draft, says it "does not establish any rights for any person and is not binding on HHS or the public," and opens comments for two weeks after publication, which on our arithmetic runs to November 13, 2026. HHS says it may revisit the policy if a safety signal or product quality issue arises. It states that FDA's future rulemakings "may propose adding some or all of these peptides to the 503A bulks list." HHS justifies including BPC-157 by pointing to new evidence of historical use, a certificate from an FDA-registered facility, and the policy's own testing and reporting conditions.

On our reading, the policy does three things and no more. It is a statement about federal enforcement, not an approval, and FDA has still not reviewed any BPC-157 product for safety or effectiveness. It covers compounding for a patient, not retail sale. And it says nothing about state law: state boards of pharmacy license the pharmacies that would do this work.

FDA's reviewers found BPC-157 products offered online as capsules, sprays and injectables. Some sellers label vials "research use only" or "not for human consumption", and FDA does not treat that label as decisive. In a June 2023 warning letter to an online seller whose products included injectable and nasal BPC-157, FDA wrote that "despite statements on your product labeling marketing your products for 'research purpose only' and 'not for human consumption,' evidence obtained from your website establishes that your products are intended to be drugs for human use," and called the products unapproved new drugs. An August 2026 FDA warning letter to another peptide seller repeats the reasoning and adds that selling bacteriostatic water to reconstitute the vials is itself evidence of intended use as an injectable drug.

The HHS policy describes its own purpose as discouraging "the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients." Nothing in it extends to those products. FDA's letters are addressed to sellers; we found no FDA statement about individuals who buy for their own use, and this page is not legal advice.

The World Anti-Doping Agency's 2026 Prohibited List, in effect from January 1, 2026, names BPC-157 under S0, non-approved substances: any pharmacological substance with "no current approval by any governmental regulatory health authority for human therapeutic use" is prohibited at all times. An HHS enforcement policy is not a regulatory approval for therapeutic use, so on our reading it does not change an athlete's position. Anyone subject to testing should check with their anti-doping organization.

If you are considering BPC-157, start from what FDA's reviewers found: no human studies by the routes proposed for compounding, and too little information to know whether it causes harm. The only route HHS has said it does not intend to act against runs through a prescriber and a state-licensed compounding pharmacy, under conditions you can check. Ask the prescriber which pharmacy will compound it and confirm that pharmacy's license with its state board, using the lookup steps in our guide to what the FDA says about compounded GLP-1s. A product made under the HHS policy should carry a single active ingredient and the label line "This is a compounded drug product. Not for resale." For what an online prescriber may and may not prescribe, see our guide to online prescribing rules.

If you have used BPC-157 and had a reaction, tell a clinician and report it to FDA MedWatch; FDA had three reports on file when it reviewed the substance. And if the real question is your recovery, joints or gut, your personal screening plan sets out the tests and screenings that have evidence behind them for your age and sex.